# Innovent Biologics and Pfizer have entered a groundbreaking partnership, valued at $10.5 billion.

*biotech · news · 2026-05-30 · Devdiscourse*

## Key points

- Innovent Biologics and Pfizer signed a $10.5 billion partnership to develop 12 cancer drugs.
- Pfizer will pay Innovent $650 million upfront, with potential for further milestone-based payments.
- The agreement focuses on early-stage oncology drugs and leverages China's growing biotech capabilities.
- This deal marks a new scale of collaboration between Western and Asian pharmaceutical companies.

Innovent Biologics and Pfizer have entered a groundbreaking partnership, valued at $10.5 billion, to develop a dozen early-stage cancer drugs. This strategic move capitalizes on China's thriving biotech industry. The agreement includes an upfront payment of $650 million to Innovent and anticipates additional payments based on developmental milestones. This deal reflects a global push among pharmaceutical giants to leverage the rapidly expanding biotech sector in Asia, highlighting an increasing collaboration between Western and Asian drug developers. (With inputs from agencies.)

**Companies:** Pfizer, Innovent Biologics
**Countries:** China, United States

[Read the full story on Devdiscourse](https://www.devdiscourse.com/article/health/3926961-cancer-collaboration-soars-innovent-and-pfizers-105b-biotech-boom)

---

Canonical: https://newsio.io/n/daa0b0f8-24fc-4793-9c55-3ec2b4503f35/innovent-biologics-and-pfizer-have-entered-a-groundbreaking-partnership-valued-a
Summarized by Newsio from Devdiscourse. https://newsio.io/how-it-works